Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

PTH and ALP values were higher, while vitamin D, calcium, and magnesium concentrations were lower (all p < 0.01).

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This retrospective cohort study was conducted at King Abdulaziz Medical City (KAMC) in Riyadh, Saudi Arabia, a tertiary-level referral center with one of the largest NICUs in the region.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Metabolic bone disease in extremely preterm infants: incidence, risk factors, and outcomes from a structured bone health program

Cohort study · Frontiers in Pediatrics · 2025

Original publication title

Metabolic bone disease in extremely preterm infants: incidence, risk factors, and outcomes from a structured bone health program

Saif Alsaif; Mohanned Alrahili; Talal Aljarbou; Lina Alsherbini; Mohammad Maghoula; Alanoud Alluwaymi; Mesaed Alsenani; Abdulrahman Altuwaym; Faisal Alamer; Abdulrahman Mandurah; Beverly Baylon; Ibrahim Ali; Kamal Ali

© 2025 Alsaif, Alrahili, Aljarbou, Alsherbini, Maghoula, Alluwaymi, Alsenani, Altuwaym, Alamer, Mandurah, Baylon, Ali and Ali.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

MBD is common in extremely preterm infants and is associated with growth failure and prolonged hospitalization. A 4-week PTH screen showed good discrimination for radiologic osteopenia (AUC 0.78), supporting its role within structured bone health care. As our findings are based on a biochemical definition, diagnostic thresholds require external validation.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Metabolic bone disease (MBD) of prematurity is a common disorder in extremely preterm and extremely low-birth-weight (ELBW) infants. However, regional data on this disorder from the Middle East are limited. We evaluated the incidence, risk factors, biochemical markers, and outcomes of MBD in infants born at <28 weeks of gestation and <1,000 g.

Source: Background

Abstract: What methods does the paper describe?

Our retrospective cohort included 487 inborn preterm infants admitted to a tertiary NICU (Riyadh, Saudi Arabia; 2017 to 2024). MBD was defined as PTH >18 pmol/L at 4 weeks; ROC against radiographic osteopenia showed good discrimination (AUC 0.78). The clinical characteristics, nutrient intake, growth, and biochemical markers (ALP, phosphate, calcium, vitamin D, PTH) of the infants were analyzed. Logistic regression identified predictors and associations with adverse outcomes.

Source: Methods

Abstract: Discussion

Within this <28-week cohort, skeletal complications were less frequent than suggested by many reports, plausibly reflecting a structured bone health program (routine biochemical screening, optimized mineral delivery, and minimal handling). Findings support the incorporation of PTH alongside ALP for earlier detection and point to modifiable exposures (prolonged TPN, diuretics, and steroids) as targets for prevention. Prospective multicenter validation with standardized thresholds and imaging strategies is warranted.

Source: Discussion

Abstract: Results

MBD was diagnosed in 202 out of 487 infants (41.5%). Compared with infants without MBD, those with MBD had lower GA and birth weight (both p < 0.001), more postnatal steroid exposure (44% vs. 27%, p < 0.001), longer diuretic therapy (12% vs. 3.5%, p < 0.001), and TPN beyond 28 days (50% vs. 31%, p < 0.001). PTH and ALP values were higher, while vitamin D, calcium, and magnesium concentrations were lower (all p < 0.01). Despite similar calcium/phosphate intakes, MBD was associated with postnatal growth failure (77% vs. 64%, p = 0.005), hospitalization of >60 days (88% vs. 70%, p < 0.001), and discharge on mineral supplements (36% vs. 16%, p < 0.001).

Radiologic osteopenia occurred in 17.3% of MBD infants (7.1% overall), while fractures were uncommon (1.8% overall; 4.4% in MBD). On multivariable analysis, MBD independently predicted fractures (aOR: 8.3, 95% CI: 1.01 to 68.3), prolonged hospitalization (aOR: 1.9, 95% CI: 1.09 to 3.29), and growth failure (aOR: 1.63, 95% CI: 1.06 to 2.53).

Source: Results

Abstract: Conclusion

MBD is common in extremely preterm infants and is associated with growth failure and prolonged hospitalization. A 4-week PTH screen showed good discrimination for radiologic osteopenia (AUC 0.78), supporting its role within structured bone health care. As our findings are based on a biochemical definition, diagnostic thresholds require external validation.

Source: Conclusion
Authors’ abstract

Background

Metabolic bone disease (MBD) of prematurity is a common disorder in extremely preterm and extremely low-birth-weight (ELBW) infants. However, regional data on this disorder from the Middle East are limited. We evaluated the incidence, risk factors, biochemical markers, and outcomes of MBD in infants born at <28 weeks of gestation and <1,000 g.

Methods

Our retrospective cohort included 487 inborn preterm infants admitted to a tertiary NICU (Riyadh, Saudi Arabia; 2017 to 2024). MBD was defined as PTH >18 pmol/L at 4 weeks; ROC against radiographic osteopenia showed good discrimination (AUC 0.78). The clinical characteristics, nutrient intake, growth, and biochemical markers (ALP, phosphate, calcium, vitamin D, PTH) of the infants were analyzed. Logistic regression identified predictors and associations with adverse outcomes.

Results

MBD was diagnosed in 202 out of 487 infants (41.5%). Compared with infants without MBD, those with MBD had lower GA and birth weight (both p < 0.001), more postnatal steroid exposure (44% vs. 27%, p < 0.001), longer diuretic therapy (12% vs. 3.5%, p < 0.001), and TPN beyond 28 days (50% vs. 31%, p < 0.001). PTH and ALP values were higher, while vitamin D, calcium, and magnesium concentrations were lower (all p < 0.01). Despite similar calcium/phosphate intakes, MBD was associated with postnatal growth failure (77% vs. 64%, p = 0.005), hospitalization of >60 days (88% vs. 70%, p < 0.001), and discharge on mineral supplements (36% vs. 16%, p < 0.001).

Radiologic osteopenia occurred in 17.3% of MBD infants (7.1% overall), while fractures were uncommon (1.8% overall; 4.4% in MBD). On multivariable analysis, MBD independently predicted fractures (aOR: 8.3, 95% CI: 1.01 to 68.3), prolonged hospitalization (aOR: 1.9, 95% CI: 1.09 to 3.29), and growth failure (aOR: 1.63, 95% CI: 1.06 to 2.53).

Discussion

Within this <28-week cohort, skeletal complications were less frequent than suggested by many reports, plausibly reflecting a structured bone health program (routine biochemical screening, optimized mineral delivery, and minimal handling). Findings support the incorporation of PTH alongside ALP for earlier detection and point to modifiable exposures (prolonged TPN, diuretics, and steroids) as targets for prevention. Prospective multicenter validation with standardized thresholds and imaging strategies is warranted.

Conclusion

MBD is common in extremely preterm infants and is associated with growth failure and prolonged hospitalization. A 4-week PTH screen showed good discrimination for radiologic osteopenia (AUC 0.78), supporting its role within structured bone health care. As our findings are based on a biochemical definition, diagnostic thresholds require external validation.

Publication and source details

Original title: Metabolic bone disease in extremely preterm infants: incidence, risk factors, and outcomes from a structured bone health program

Saif Alsaif; Mohanned Alrahili; Talal Aljarbou; Lina Alsherbini; Mohammad Maghoula; Alanoud Alluwaymi; Mesaed Alsenani; Abdulrahman Altuwaym; Faisal Alamer; Abdulrahman Mandurah; Beverly Baylon; Ibrahim Ali; Kamal Ali

Frontiers in Pediatrics · 2025

* Correspondence: Kamal Ali Alika@mngha.med.sa© 2025 Alsaif, Alrahili, Aljarbou, Alsherbini, Maghoula, Alluwaymi, Alsenani, Altuwaym, Alamer, Mandurah, Baylon, Ali and Ali.2025Alsaif, Alrahili, Aljarbou, Alsherbini, Maghoula, Alluwaymi, Alsenani, Altuwaym, Alamer, Mandurah, Baylon, Ali and Alihttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declare that no financial support was received for the research and/or publication of this article.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:45:18.995362+00:00

DOI: 10.3389/fped.2025.1676540 · PMC12685821